Bioinformatics company DNAnexus Inc. raised $100 million in financing to expand its global reach in clinical diagnostic and pharmaceutical markets and medical centers. Perceptive Advisors and Northpond Ventures LLC led the round, joined by new...

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...

Janssen Pharmaceuticals Inc. said a preplanned analysis by an IDMC showed that Erleada apalutamide met the dual primary endpoints in the Phase III TITAN trial to treat metastatic castration-sensitive prostate cancer (CSPC). The Johnson &...

Janssen Pharmaceuticals Inc. said a preplanned analysis by an IDMC showed that Erleada apalutamide met the dual primary endpoints in the Phase III TITAN trial to treat metastatic castration-sensitive prostate cancer (CSPC). The Johnson &...

In a draft evidence report, ICER found that newer extended-release formulations of medication-assisted treatments (MATs) for opioid use disorder were not cost-effective compared with generic medicines. The institute compared the clinical effectiveness and value of...

In a draft evidence report , ICER found that newer extended-release formulations of medication-assisted treatments (MATs) for opioid use disorder were not cost-effective compared with generic medicines. The institute compared the clinical effectiveness and value of...

In a draft scoping document published April 26, ICER said it will consider a broad set of outcomes in its review of three buprenorphine products as medication-assisted treatments for opioid use disorder. ICER is poised...

In a draft scoping document published Thursday, ICER said it will consider a broad set of outcomes in its review of three buprenorphine products as medication-assisted treatments for opioid use disorder. ICER is poised to...

The Institute for Clinical and Economic Review said it will develop a report that will compare the clinical effectiveness of three buprenorphine products to commonly used drugs for medication-assisted treatment of opioid use disorder. In...

The Institute for Clinical and Economic Review said it will develop a report that will compare the clinical effectiveness of three buprenorphine products to commonly used drugs for medication-assisted treatment of opioid use disorder. In...